found that two or more secondary mutations are associated with a particularly poor prognosis versus the requirement of only a single mutation for MDS‐related AML and included additional mutations in RUNX1, as well as NF1, CUX1, PHF6, SETBP1, and KMT2APTD in defining secondary mutations [7]. This evidence concerns the gene NF1 and myelodysplastic syndrome.